317 related articles for article (PubMed ID: 34092252)
21. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis.
Lloyd KA; Wigerblad G; Sahlström P; Garimella MG; Chemin K; Steen J; Titcombe PJ; Marklein B; Zhou D; Stålesen R; Ossipova E; Lundqvist C; Ekwall O; Rönnelid J; Mueller DL; Karlsson MCI; Kaplan MJ; Skriner K; Klareskog L; Wermeling F; Malmström V; Grönwall C
Front Immunol; 2018; 9():3033. PubMed ID: 30662440
[TBL] [Abstract][Full Text] [Related]
22. Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis.
Darrah E; Davis RL; Curran AM; Naik P; Chen R; Na CH; Giles JT; Andrade F
Arthritis Rheumatol; 2020 Sep; 72(9):1476-1482. PubMed ID: 32255561
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
[TBL] [Abstract][Full Text] [Related]
24. Subjects at-risk for future development of rheumatoid arthritis demonstrate a PAD4-and TLR-dependent enhanced histone H3 citrullination and proinflammatory cytokine production in CD14
Okamato Y; Ghosh T; Okamoto T; Schuyler RP; Seifert J; Charry LL; Visser A; Feser M; Fleischer C; Pedrick C; August J; Moss L; Bemis EA; Norris JM; Kuhn KA; Demoruelle MK; Deane KD; Ghosh D; Holers VM; Hsieh EWY
J Autoimmun; 2021 Feb; 117():102581. PubMed ID: 33310262
[TBL] [Abstract][Full Text] [Related]
25. Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
Darrah E; Yu F; Cappelli LC; Rosen A; O'Dell JR; Mikuls TR
Arthritis Rheumatol; 2019 May; 71(5):696-702. PubMed ID: 30507066
[TBL] [Abstract][Full Text] [Related]
26. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility.
Sur Chowdhury C; Giaglis S; Walker UA; Buser A; Hahn S; Hasler P
Arthritis Res Ther; 2014 Jun; 16(3):R122. PubMed ID: 24928093
[TBL] [Abstract][Full Text] [Related]
27. Protein Citrullination by Peptidyl Arginine Deiminase/Arginine Deiminase Homologs in Members of the Human Microbiota and Its Recognition by Anti-Citrullinated Protein Antibodies.
Pérez-Pérez ME; Nieto-Torres E; Bollain-Y-Goytia JJ; Delgadillo-Ruíz L
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791230
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
Zhao J; Zhao Y; He J; Jia R; Li Z
J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic values, association with disease activity and possible risk factors of anti-PAD4 in rheumatoid arthritis: a meta-analysis.
Zhang G; Xu J; Du D; Liu Y; Dai L; Zhao Y
Rheumatology (Oxford); 2024 Apr; 63(4):914-924. PubMed ID: 37824204
[TBL] [Abstract][Full Text] [Related]
30. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.
Li B; Li P; Bi L
Clin Rheumatol; 2020 Mar; 39(3):899-907. PubMed ID: 31758423
[TBL] [Abstract][Full Text] [Related]
31. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine.
Martinez-Prat L; Palterer B; Vitiello G; Parronchi P; Robinson WH; Mahler M
Expert Rev Clin Immunol; 2019 Oct; 15(10):1073-1087. PubMed ID: 31524005
[No Abstract] [Full Text] [Related]
32. Lack of Association among Peptidyl Arginine Deiminase Type 4 Autoantibodies,
Guderud K; Mæhlen MT; Nordang GBN; Viken MK; Andreassen BK; Molberg Ø; Flåm ST; Lie BA
J Rheumatol; 2018 Aug; 45(9):1211-1219. PubMed ID: 29858238
[TBL] [Abstract][Full Text] [Related]
33. Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis.
Jonsson MK; Kantyka T; Falkowski K; Aliko A; Aga AB; Lillegraven S; Sexton J; Fevang BT; Mydel P; Haavardsholm EA
Scand J Rheumatol; 2020 Mar; 49(2):87-95. PubMed ID: 31544586
[No Abstract] [Full Text] [Related]
34. Autocitrullination confers monocyte chemotactic properties to peptidylarginine deiminase 4.
Yoshida K; Ito H; Kurosaka D; Ikeda R; Noda K; Saito M; Kurosaka D
Sci Rep; 2023 May; 13(1):7528. PubMed ID: 37160933
[TBL] [Abstract][Full Text] [Related]
35. Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.
Shimada A; Kobayashi T; Ito S; Okada M; Murasawa A; Nakazono K; Yoshie H
J Periodontal Res; 2016 Feb; 51(1):103-11. PubMed ID: 26094771
[TBL] [Abstract][Full Text] [Related]
36. Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures.
Uysal-Onganer P; D'Alessio S; Mortoglou M; Kraev I; Lange S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573274
[TBL] [Abstract][Full Text] [Related]
37. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets.
Curran AM; Naik P; Giles JT; Darrah E
Nat Rev Rheumatol; 2020 Jun; 16(6):301-315. PubMed ID: 32341463
[TBL] [Abstract][Full Text] [Related]
38. Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis.
Roos Ljungberg K; Börjesson E; Martinsson K; Wetterö J; Kastbom A; Svärd A
Arthritis Res Ther; 2020 Nov; 22(1):274. PubMed ID: 33225988
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritis.
Ren J; Sun L; Zhao J
Clin Rheumatol; 2017 Nov; 36(11):2431-2438. PubMed ID: 28887697
[TBL] [Abstract][Full Text] [Related]
40. The lack of association between PADI4_94 or PADI4_104 polymorphisms and RF, ACPA and anti-PAD4 in patients with rheumatoid arthritis.
Ciesla M; Kolarz B; Darmochwal-Kolarz D
Sci Rep; 2022 Jul; 12(1):11882. PubMed ID: 35831381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
